Kelley Marie Weinfurtner, MD

She/her
Gastroenterology
Accepting new patients
Sees patients age 18 and up
Penn Gastroenterology Perelman
Make an appointmentCall 215-349-8222
Penn Medicine Provider

About me

  • Assistant Professor of Medicine (Gastroenterology) at the Hospital of the University of Pennsylvania

I am a transplant hepatologist who cares for patients with a wide range of liver problems. In particular, I have significant expertise in caring for patients with advanced liver disease and patients with liver tumors. In addition, I have a research program centered around developing precision medicine strategies for patients with primary liver cancers.

My education and training

  • Medical School: University of California San Francisco
  • Residency: University of California San Francisco
  • Fellowship: University of Pennsylvania Health System

Spoken languages

English
English

Insurance accepted

Please contact the practice and/or the member services department of your insurance company for specific details before receiving services. Providers may participate in some, but not all, products offered by a health plan; providers may also accept plans at some practice locations but not others.

Locations

Penn Medicine hospital privileges

  • Hospital of the University of Pennsylvania: Has privileges to treat patients in the hospital.
  • Pennsylvania Hospital: Has privileges to treat patients in the hospital.
  • Penn Presbyterian Medical Center: Has privileges to treat patients in the hospital.
Dr. Weinfurtner is a Penn Medicine physician.

Qualifications and experience

Treatments and Conditions

Research

Publications

Yan L, Huang L, Wright C, Gade TPF, Weinfurtner K Intra-patient tumor-level outcomes of transarterial chemoembolization versus transarterial radioembolization for multifocal hepatocellular carcinoma , Society of Interventional Oncology Annual Meeting: 2026

Weinfurtner K, Amin R, Skuli N, Gade TPF, Kaplan DE Patient-derived models of liver cancer to inform therapeutic decision: recent updates , Seminars in Liver Disease: 2026

Boehmler D, Baron R, Crainic J, Islam A, Kim Y, Gurevich A, Perkons N, Zavriyev A, Amin R, Andrew-Udoh J, Tuzneen Supan E, El Ghazal R, Hunt SJ, McClung G, Tischfield D, Ackerman D, Weljie A, Weinfurtner K, Skuli N, Gade TPF. Locoregional Lactate Dehydrogenase Inhibition Potentiates Therapy and Overcomes Treatment Resistance in Hepatocellular Carcinoma , Hepatology: 2026

Kim Y, McClung G, Wright C, Tischfield D, Furth EE, Kaffe E, Weinfurtner K, Gade TPF Hepatocyte Humanization in an SRG Rat Model After Partial Hepatectomy , AASLD The Liver Meeting : 2025

Hoteit MA, Abt PL, Priore SF, Tondon R, Abu-Gazala A, Agarwal P, Weinfurtner K, Hilscher MB, Wangensteeen KJ Molecular patterns associated with recurrence and survival in intrahepatic cholangiocarcinoma (iCCA) / hepatocholangiocarcinoma (HCC-CCA) after liver transplantation , AASLD The Liver Meeting: 2025

Ferrante ND, Hubbard RA, Weinfurtner K, Mezina AI, Newcomb CW, Furth EE, Bhattacharya D, Njei B, Taddei, TH, Singal A, Hoteit MA, Park LS, Kaplan DE, Lo Re V. Validity of Diagnostic Codes and Laboratory Tests to Identify Cholangiocarcinoma and Its Subtypes , Pharmacoepidemiol Drug Saf, 34(5): 2025,e70154

Hoteit M, Weinfurtner K Recurrent hepatocellular carcinoma after liver transplantation: Small steps, while awaiting a breakthrough. , Liver Transplantation: 2025

Weinfurtner K, Tischfield D, McClung G, Crainic J, Gordan J, Jiao J, Furth EE, Li W, Tuzneen Supan E, Nadolski GJ, Hunt SJ, Kaplan DE, Gade TPF Human GM-CSF/IL-3 enhance tumor immune infiltration in humanized HCC patient-derived xenografts , JHep Reports, 7(3): 2025,101264

Willis E, Verrelle J, Secreto A, Cole S, McClung G, Weinfurtner K, Gade TP, Radaelli E Diagnostic Challenge in Veterinary Pathology: Otitis Media in a Humanized NOG-EXL Mouse , Vet Pathol, 62(2): 2025,113-116

Huang L, Dang QA, Wright, C, Gade TPF, Weinfurtner, K Comparison of treatment response to chemoembolization and radioembolization in patients with intermediate stage hepatocellular carcinoma. , Society of Interventional Oncology Annual Meeting: 2025